GlassScriptPhysician profile
William Samuel Boyd
NPI 1982143228
$4,996.17
in general payments reported to CMS, 2019-2025
37 companies · $566 in 2025
The $566 reported for 2025 was more than what 79% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,864 · 2023: $603 · 2024: $963 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,131.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $787.43 | 2022 | |
| Abbvie INC. | $526.95 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $525.69 | 2022-2025 | |
| Inari Medical, INC. | $411.46 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Pfizer INC. | $218.97 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $203.99 | 2022-2024 | Xarelto |
| Csl Behring | $195.29 | 2022 | |
| Lilly USA, LLC | $185.71 | 2022-2025 | Amyvid, Kisunla |
| Biogen, INC. | $182.71 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $181.16 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $160.60 | 2022-2023 | Austedo Xr |
| Alexion Pharmaceuticals, INC. | $130.56 | 2022-2024 | Ultomiris |
| Acorda Therapeutics, INC | $126.67 | 2022-2023 | Inbrija |
| Neurocrine Biosciences, INC. | $116.16 | 2022 | |
| Ucb, INC. | $114.10 | 2024-2025 | Rystiggo, Nayzilam |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $108.68 | 2022-2025 | Uplizna |
| Lundbeck LLC | $92.46 | 2022-2023 | Vyepti |
| Sunovion Pharmaceuticals INC. | $71.29 | 2022 | |
| Horizon Therapeutics Plc | $66.63 | 2022-2023 | Uplizna |
| Sk Life Science, INC. | $66.48 | 2022 | |
| Emd Serono, INC. | $64.67 | 2022 | |
| Celgene Corporation | $60.96 | 2022-2023 | Zeposia |
| Supernus Pharmaceuticals, INC. | $58.67 | 2022 | |
| Neurelis, INC. | $58.27 | 2022 | |
| Gilead Sciences, INC. | $28.82 | 2023 | |
| Eisai INC. | $27.31 | 2023 | |
| Lantheus Medical Imaging, INC. | $23.93 | 2025 | |
| Janssen Biotech, INC. | $23.13 | 2025 | |
| Melinta Therapeutics, LLC | $22.27 | 2025 | Rezzayo, Kimyrsa |
| Impel Pharmaceuticals INC. | $22.20 | 2023 | Trudhesa |
| Takeda Pharmaceuticals U.S.A., INC. | $22.01 | 2025 | Hyqvia |
| Genzyme Corporation | $20.10 | 2022 | |
| Avion Pharmaceuticals | $19.00 | 2022 | |
| Mdd US Operations, LLC | $18.69 | 2022 | |
| Genentech USA, INC. | $18.62 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.51 | 2022 | |
| Acadia Pharmaceuticals INC | $17.02 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.